BNTXN Stock Chart & Stats
$1590.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1590.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,410.00 - $2,400.00
Previous CloseN/A
Volume0.00
Average Volume (3M)20.00
Market Cap
$396.76B
Enterprise Value$12.60K
Total Cash (Recent Filing)$14.65B
Total Debt (Recent Filing)$303.12M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Nov 03, 2026EPS Estimate
14.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.09
Shares Outstanding252,884,260
10 Day Avg. Volume0
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.02
Price to Sales (P/S)7.10
P/FCF Ratio72.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,160.56Price Target Upside35.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-78.44
Revenue Forecast (FY)$37.32B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthBioNTech's substantial liquidity (EUR 16.6B) and very low leverage provide durable financial flexibility to fund late‑stage trials, absorb operating losses, pursue manufacturing scale-ups, and execute share repurchases without immediate financing needs over the next several quarters.
Late‑stage Oncology PipelineAdvancing multiple registrational programs (Phase III LCD, pumitamig pivotal programs, gotistobart pivotal-stage interim readouts) materially diversifies BioNTech beyond seasonal vaccines. Successful readouts could create multi-year oncology revenue streams and reduce reliance on COVID vaccine demand.
MRNA Platform & Regulatory ValidationEC authorization for an XFG‑adapted vaccine validates BioNTech's mRNA platform, regulatory and manufacturing capabilities. Producing adapted seasonal vaccines at risk and supply readiness supports recurring seasonal demand and reinforces the Pfizer collaboration as a durable commercial channel.
Bears Say
Revenue Decline & ConcentrationA sharp, persistent drop in vaccine demand and a downward revenue guidance reduce topline predictability. Management also flags H2 concentration (large collaboration payments), meaning timing shifts materially affect near‑term cash flow and make revenue durability uncertain over the next 2–6 months.
Operating Losses & Cost PressureDespite high gross margins, aggressive R&D and rising SG&A (commercial build, integration, impairments) have produced deep operating losses and negative ROE. If clinical/regulatory outcomes slip or approvals are delayed, continued high spending will pressure capital and lengthen time to sustainable profitability.
Intellectual Property Litigation RiskMulti‑jurisdictional LNP patent suits raise the risk of injunctions, royalties or remediation across many European countries. Protracted litigation could restrict manufacturing/sales, impose sizable settlements or operational constraints, and create regulatory and commercial uncertainty spanning multiple years.
BioNTech SE News
BNTXN FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $1410.00 and its highest was $2400.00 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is $396.76B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Nov 03, 2026 which is in 89 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Aug 04, 2026. The company reported -$64.537 earnings per share for the quarter, missing the consensus estimate of -$41.829 by -$22.707.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE does not currently pay dividends.
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is 14.72.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 252,884,260 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -$64.537 in its last earnings report, missing expectations of -$41.829. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in MX:BNTXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioNTech SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2,160.56 (35.88% Upside)
$2,160.56 (35.88% Upside)
Blogger Sentiment
Bullish
MX:BNTXN Sentiment 78%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 78%
Bearish news 22%
Bearish news 22%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.12%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
BNTXN Company Deck
BNTXN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balances meaningful near‑term financial headwinds (sharp Q2 revenue decline, guidance reduction, increased SG&A and some timeline pushes) against substantial clinical and strategic progress: multiple encouraging Phase II signals (pumitamig, gotistobart), initiation of a Phase III for LCD, continued advancement of mRNA oncology programs, a strong cash position (EUR 16.6B) and active capital return. The pipeline momentum and capital strength mitigate short‑term revenue weakness, but the quarter highlights both execution progress and clear near‑term commercial challenges.View all MX:BNTXN earnings summariesBNTXN Stock 12 Month Forecast
Average Price Target
$2,160.56
▲(35.88% Upside)